Regulatory Statement: For Research Use Only. Not for any animal or human therapeutic or diagnostic use.
Cleavage: No Cleavage Site
Vector Type: pENTR
Product Size: 10 µg
Cloning Method: Gateway®
Protein Tag or Fusion: Untagged
Antibiotic Resistance (Bacterial): Kanamycin (KanR), Chloramphenicol (CmR)
The Gateway® entry vectors (Table 1) offer the following:
attL1 and attL2 sites for site-specific recombination of the entry clone with a Gateway® destination vector to ensure cloning of the gene of interest in the correct orientation for expression
Kozak consensus sequence for efficient translation initiation in eukaryotic systems
Ribosome binding site for efficient translation initiation in prokaryotic systems (pENTR™ 1A Dual Selection, pENTR™3C Dual Selection, and pENTR™11 Dual Selection vectors only)
rrnB transcription termination sequences to prevent basal expression of the PCR product of interest in E. coli
pUC origin for high-copy replication and maintenance of the plasmid in E. coli
Kanamycin resistance gene for selection in E. coli
The ccdB⁄chloramphenicol fusion gene located between the two attL sites for
negative selection and
Chloramphenicol selection in E. coli
Kanamycin resistance gene for selection in E. coli
Gateway® entry vectors are designed to clone DNA sequences using restriction endonucleases and ligase to create a Gateway® entry clone. The resulting entry clone is ready for recombination with a destination vector to create an expression clone. New: pENTR™ Dual Selection vectors!